1. SUB-TYPE OF MDS: Patients with AML and MDS undergoing reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT)
2. SEVERITY OF MDS: Intermediate – 2 or High Risk
3. NAME OF DRUG: Novel conditioning regimen: fludarabine/cytarabine/amsacrine/busulphan/ATG (FLAMSA-BU)
4. Aims and benefits: This is a randomised controlled trial comparing the novel conditioning regimen FLAMSA-BU with standard conditioning regimens fludarabine/melphalan/alemtuzumab (FMA), fludarabine/busulphan/alemtuzumab (FBA) or fludarabine/busulphan/ATG (FB-ATG).
   • It compares the benefits in terms of toxicity, disease relapse and overall survival.
5. Basic inclusion criteria:
   • Patients with AML or MDS in whom a RIC allograft is clinically indicated.
   • ECOG performance status of 0, 1 or 2
6. Basic exclusion criteria:
   • Patients with chemo-refractory relapse of AML or MDS
   • Patients with contraindications to receiving RIC allogeneic SCT
   • Female patients who are pregnant or breastfeeding.
   • Kidney or liver impairment
   • Patients with active infection, HIV-positive or chronic active Hep-A, -B, -C
   • Patients with concurrent active malignancy
7. Trial sites/locations and name of physician in charge of trial: QEH, Birmingham; Churchill Hospital, Oxford; Addenbrookes, Cambridge; St James’, Leeds; Bristol Haematology and Oncology Centre; Manchester Royal Infirmary; Leicester Royal Infirmary; Royal Liverpool University Hospital; Imperial ; West of Scotland Beatson Cancer Centre; Nottingham City Hospital; Aberdeen Royal Infirmary; UCLH ; Sheffield; Derriford; King’s College Hospital.
8. More information:

Please read information and always discuss trial information with your own physician.